Suppr超能文献

通过小干扰RNA(siRNA)使乙酰肝素酶沉默可在体外和体内抑制人乳腺癌的肿瘤转移和血管生成。

Silencing of heparanase by siRNA inhibits tumor metastasis and angiogenesis of human breast cancer in vitro and in vivo.

作者信息

Zhang Zhong-Hua, Chen Yi, Zhao Hua-Jun, Xie Cheng-Ying, Ding Jian, Hou Yong-Tai

机构信息

Division of Molecular Pharmacology, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, PR China.

出版信息

Cancer Biol Ther. 2007 Apr;6(4):587-95. doi: 10.4161/cbt.6.4.3888.

Abstract

Expression of the heparanase gene is associated with invasive, angiogenic and metastatic potential of diverse malignant tumors and cell lines. Here we used RNA interference strategies to evaluate the role of human heparanase in breast malignancy and to explore the therapeutic potential of its specific targeting. The siRNA targeting human heparanase almost completely inhibited the expression of heparanase in human breast carcinoma MDA-MB-435 cells, whereas the mismatched siRNA showed no effect. Cells transfected with heparanase siRNA expressed significantly less heparanase and profoundly reduced invasion and adhesion in vitro. In MDA-MB-435 cell xenograft model, tumors treated with siRNA were less vascularized and less metastatic than those treated with saline and the mismatched controls. The association of reduced levels of heparanase and altered tumorigenic properties in cells with anti-heparanase siRNA indicates that heparanase is important in cancer progress and has potential use as a target for anticancer drug development.

摘要

乙酰肝素酶基因的表达与多种恶性肿瘤和细胞系的侵袭、血管生成及转移潜能相关。在此,我们运用RNA干扰策略来评估人乙酰肝素酶在乳腺恶性肿瘤中的作用,并探索其特异性靶向的治疗潜力。靶向人乙酰肝素酶的小干扰RNA(siRNA)几乎完全抑制了人乳腺癌MDA-MB-435细胞中乙酰肝素酶的表达,而错配的siRNA则无此作用。用乙酰肝素酶siRNA转染的细胞表达的乙酰肝素酶显著减少,且体外侵袭和黏附能力大幅降低。在MDA-MB-435细胞异种移植模型中,与用生理盐水及错配对照处理的肿瘤相比,用siRNA处理的肿瘤血管化程度较低且转移较少。抗乙酰肝素酶siRNA处理的细胞中乙酰肝素酶水平降低与致瘤特性改变之间的关联表明,乙酰肝素酶在癌症进展中起重要作用,并且有潜力用作抗癌药物开发的靶点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验